

1 **Title: Microbiome disturbance and resilience dynamics of the upper**  
2 **respiratory tract in response to influenza A virus infection in humans**  
3 **and ferrets**

4  
5 **Authors:** Drishti Kaul<sup>1,8</sup>, Raveen Rathnasinghe<sup>2,8</sup>, Marcela Ferres<sup>2</sup>, Gene S. Tan<sup>1,3</sup>, Aldo  
6 Barrera<sup>2,4</sup>, Brett E. Pickett<sup>5</sup>, Barbara A. Methe<sup>5a</sup>, Suman Das<sup>5</sup>, Isolda Budnik<sup>2</sup>, Rebecca A.  
7 Halpin<sup>5</sup>, David Wentworth<sup>5b</sup>, Mirco Schmolke<sup>6c</sup>, Ignacio Mena<sup>6</sup>, Randy A. Albrecht<sup>6</sup>, Indresh  
8 Singh<sup>5</sup>, Karen E. Nelson<sup>5</sup>, Adolfo García-Sastre<sup>6,7</sup>, Chris L. Dupont<sup>1\*</sup>, Rafael A. Medina<sup>2,4,6\*</sup>.

9  
10 **Affiliations:**

11 <sup>1</sup>J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA.

12 <sup>2</sup>Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, Facultad de Medicina,  
13 Pontificia Universidad Católica de Chile, Santiago, Chile.

14 <sup>3</sup> Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037,  
15 USA

16 <sup>4</sup>Millennium Institute on Immunology and Immunotherapy, Santiago, Chile

17 <sup>5</sup>J. Craig Venter Institute, 9704 Medical Center Drive, Rockville, Maryland 20850, 14 USA.

18 <sup>6</sup>Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of  
19 Medicine at Mount Sinai, New York, NY 10029, USA.

20 <sup>7</sup>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029,  
21 USA.

22 <sup>8</sup>These authors contributed equally to this work

23 <sup>a</sup> University of Pittsburgh, Department of Medicine, Pittsburgh PA 15213

24 <sup>b</sup> Present address: National Center for Immunization and Respiratory Diseases, Centers for  
25 Disease Control and Prevention, Atlanta, GA, USA.

26 <sup>c</sup> Present address: Department of Microbiology and Molecular Medicine, University of Geneva,  
27 Switzerland

28 \*Corresponding author: E-mail: [rmedinas@med.puc.cl](mailto:rmedinas@med.puc.cl) (Lead Contact), [cdupont@jcvl.org](mailto:cdupont@jcvl.org)

29

30 **One Sentence Summary: Dynamics of the upper respiratory tract microbiome during**  
31 **influenza A virus infection**

32

33 **Abstract:**

34 Infection with influenza can be aggravated by bacterial co-infections, which often results in  
35 disease exacerbation because of host responses and cellular damage. The native upper respiratory  
36 tract (URT) microbiome likely plays a role, yet the effects of influenza infection on the URT  
37 microbiome are largely unknown. We performed a longitudinal study to assess the temporal  
38 dynamics of the URT microbiomes of uninfected and influenza virus-infected humans and  
39 ferrets. Uninfected human patients and ferret URT microbiomes had stable “healthy ecostate”  
40 communities both within and between individuals. In contrast, infected patients and ferrets

41 exhibited large changes in bacterial community composition over time and between individuals.  
42 The “unhealthy” ecostates of infected individuals progressed towards the “healthy ecostate” over  
43 time, coinciding with viral clearance and recovery. Blooms of *Pseudomonas* were a statistically  
44 associated constant in the disturbed microbiomes of infected individuals. The dynamic and  
45 resilient nature of the microbiome during influenza virus infection in multiple hosts provides a  
46 compelling rationale for the maintenance of the microbiome homeostasis as a potential  
47 therapeutic target to prevent IAV associated bacterial co-infections.

48

49 Keywords: Influenza A virus, resilience, biodiversity, microbiome, upper respiratory tract,  
50 H1N1, H3N2, ecostate, humans, ferrets

51 **Main Text:**

52 **Introduction**

53 Influenza A virus (IAV) is a highly infectious upper respiratory tract (URT) disease in humans  
54 and animals caused by a negative-sense segmented RNA virus. It is recognized as a major public  
55 health concern resulting yearly in significant disease and economic burden. Frequent nucleotide  
56 substitutions lead to changes on the hemagglutinin and neuraminidase glycoproteins on the  
57 surface of IAV particles (also known as antigenic drift) that contribute to the need for continuous  
58 vaccine updates. This evolutionary arms race between vaccine design and viral mutation  
59 contributes to annual influenza epidemics worldwide, which on average results in 3 to 5 million  
60 cases of severe illness and up to 291,000 to 646,000 deaths annually (1). The modular  
61 architecture of the segmented IAV genome allows for genetic re-assortment (antigenic shift) with  
62 other divergent IAVs, resulting in the sporadic emergence of novel viruses capable of causing  
63 large epidemics or pandemics. Circulation of a new IAV in the naïve human population has

64 caused pandemics in the past resulting in significant morbidity and mortality, the most notable in  
65 1918 and 1919, when the *Spanish flu* killed approximately 20 to 50 million people worldwide  
66 (2). Retrospective analyses of autopsy specimens from the 1918 pandemic revealed the  
67 prevalence of secondary superinfection caused by URT bacteria (3-5). However, the role of  
68 bacterial co-infection in disease prognosis is not only confined to pandemics; bacterial and virus  
69 co-infection during seasonal influenza epidemics are commonly associated with increase hospital  
70 admissions, severe disease and deaths (6, 7).

71  
72 Although the microbiome of non-diseased individuals is relatively stable, IAV infection has been  
73 shown to increase the diversity of bacterial taxa that are present in the URT (8). Specifically,  
74 IAV can cause changes in the relative abundances of *Staphylococcus* and *Bacteroides* genera (9),  
75 as well as *Haemophilus*, *Fusobacteria*, and other taxa (10). Temporary disturbances to the  
76 microbiome due to the changes in the local epithelia during acute or chronic conditions has also  
77 been reported as a predisposing factor for infections (11-14). The observed diversity in the  
78 human URT microbiome, together with its role in immunity and susceptibility to pathogens has  
79 been described previously (11, 15, 16). Other studies have reported that the URT microbiome  
80 may also play a beneficial role in modulating the inflammatory response induced during IAV  
81 infection (16, 17). In addition, the intestinal microbiome composition has been shown to  
82 positively regulate the toll-like receptor 7 signaling pathway following infection with IAV (18).  
83 Nonetheless, the exact mechanisms by which prior infection with IAV increase susceptibility to a  
84 secondary bacterial infection have not been determined. Importantly, the effect of IAV  
85 replication and induction of innate immune response on the composition of the human or animal  
86 URT microbiome remains to be elucidated and analyzed in depth on a community wide scale.

87 Humans and ferrets share similar lung physiology and both are known to be susceptible and  
88 transmit the same strains of the IAVs (19, 20). This has made the ferrets an ideal model to study  
89 the dynamics of IAV infection in URT. However, it is unknown whether there is similarity  
90 between the ferret and human URT microbiome in terms of composition and its temporal  
91 dynamics and modulation upon IAV infection. In this study, we examined the longitudinal  
92 diversity of the URT microbiome of influenza infected and uninfected human cohorts, as well as  
93 control uninfected and experimentally infected ferrets. These experiments revealed a strong  
94 consistency in the microbiome composition and dynamics between the two host systems,  
95 demonstrating that experimentally infected ferrets recapitulated closely the modulation of the  
96 microbiome observed in naturally infected humans. Our results suggest that microbiome  
97 disturbance and resilience dynamics may be critical to addressing the bacterial co-infections  
98 associated with influenza-derived morbidity.

99

## 100 **Results**

### 101 **Effects of influenza on the URT microbiome dynamics in human clinical samples**

102 In order to determine if the human microbiome structure is modulated by the IAV infection, we  
103 established a human cohort study and obtained nasopharyngeal swabs at multiple time points  
104 after the initial influenza-prompted hospital visits (days 1 to 22) from 30 human subjects  
105 recruited during 2011 and 2012. As healthy controls, we included nasal swab samples taken at 6  
106 time points (days 1, 2, 3, 5, 7 and 28) from 22 healthy human subjects free of any respiratory  
107 infections (Table S1). Our goal was to assess and compare the temporal microbiome biodiversity  
108 in response to ecological disturbances of the URT caused by viral infection.

109 The dynamics and relative abundances of bacteria in the URT microbiome were examined by  
110 pyrosequencing of the V1-V3 region of the 16S rRNA, which yielded a total of 2.3 million  
111 sequences, which clustered into 707 operational taxonomic units (OTUs) (Table 1). The count  
112 abundance data for the OTUs was normalized to account for the sampling process and the library  
113 size, as confounding factors for the beta-diversity analyses. Additionally, OTUs with counts less  
114 than 5 were removed to avoid inflating the importance of any contaminant sequences that might  
115 be present in the data. This resulted in over 90% of the reads mapped back to the OTUs (Table  
116 1). Metric multidimensional scaling of the beta diversity explains 38.5% of the variability across  
117 the first three components (Fig. 1). The plot shows that the IAV infection status has a strong  
118 influence on the ordination of the samples, as measured by the Bray-Curtis metric ( $R=0.649$ ,  $p$ -  
119 value  $< 0.001$ ). The uninfected and infected communities cluster away from each other (Fig. 1).  
120 Of interest, the microbiome for the IAV-infected cohort is more dynamic than that of the  
121 uninfected IAV-free cohort, validating the “Anna Karenina” principle of microbiomes, which  
122 refers to the notion that there is much more variability in the microbial communities of infected  
123 (dysbiotic) individuals than in healthy individuals. The nasopharyngeal samples from infected  
124 humans demonstrated higher diversity between infection states than within them (Fig. S1). The  $t$ -  
125 statistic for the “All within infection” versus “All between infection” for the human data set was  
126  $-150.82$  and the  $p$ -value was also significant (Table S2), which indicates that IAV infection in  
127 humans results in the clustering of microbiomes according to infection status.

128

129 **Perturbation and resilience of the human URT microbiome is not dependent on the clinical**  
130 **parameters or influenza virus subtype**

131 To complement the qualitative overview of the IAV-infected data points, we integrated  
132 additional clinical metadata including gender, antibiotic usage, age and influenza subtype; and  
133 included details of the amplification of IAV genomes from these samples to more accurately  
134 classify these data points as either positive or unknown for the presence of virus. Positive and  
135 unknown infected microbiomes were tested to determine if they were distinct enough to cluster  
136 separately based on their beta diversity. Analyses of the beta diversity metrics using PCoA,  
137 focusing just on the IAV-infected samples, did not allow deriving any conclusions from this  
138 analysis alone. In addition, the grouping of infected samples based on gender did not show any  
139 significant association (ANOSIM  $R=0.03124$ ,  $p\text{-value} < 0.023$ ), implying that there was no  
140 significant effect of gender on the clustering of the samples (Table S3). When we used distances  
141 between the samples as the response variable (ADONIS  $df\ 1$ ,  $R^2 = 0.0209$ ), only 2.1% of the  
142 variation in the distances was explained when the gender of the patients was accounted for as a  
143 predictor of the model. Hence, sex could not be correlated with the microbiome of the infected  
144 human samples. Age and effects of post visit antibiotic treatment on the microbiome trends were  
145 also examined. No significant association could be observed between post visit antibiotic usage  
146 and clustering of the infected human samples in two statistical tests (ANOSIM  $R=-0.046$ ,  $p\text{-}$   
147  $value < 0.732$ , and ADONIS  $df\ 1$ ,  $R^2 = 0.012$ ), which was surprising. However, the age of the  
148 patients seemed to have some influence on the sample grouping when all 26 categorical values  
149 were taken into consideration (ANOSIM  $R=0.47$ ,  $p\text{-value} < 0.001$ ). The statistical analyses show  
150 that while the  $p\text{-value}$  was significant, the clustering on the basis of age was only moderately  
151 strong (ADONIS  $R^2 = 0.409$ ,  $df\ 25$ ; Table S3). Since there was no indication of this effect among  
152 IAV-infected patients in the ordination plots, it is possible that the significant  $p\text{-value}$  could be  
153 attributed to the high number of samples or the differences in dispersion among the different

154 sample groupings, emphasizing the importance of considering in the analysis both the p-value  
155 and the effect size.

156

### 157 ***Pseudomonas* blooms during viral infection in the human URT**

158 We examined taxonomic profiles for all the infected and healthy patients across all the time  
159 points using the taxa abundance values for the top ten most prevalent taxa at the order level (Fig.  
160 2). All other taxa were pooled into an additional taxon named “Other”. *Pseudomonas* was the  
161 most abundant taxonomic group in all samples from influenza-infected individuals (Fig. 2, and  
162 Fig. S2 and S3). Less abundant phyla included *Bacteroidetes*, *Firmicutes*, *Actinobacteria* and  
163 some other families of *Proteobacteria*, like *Rhodanobactereceae* and *Pasteurellaceae* (c.  
164 *Gammaproteobacteria*) and *Brucellaceae* of the *Rhizobiales* order (c. *Alphaproteobacteria*).  
165 *Pseudomonas* was also clearly identified as the predominant taxon when temporal dynamic  
166 analyses were done on individuals independently (Fig. S4). As for the uninfected subjects,  
167 *Actinobacteria* was the most dominant taxon and *Pseudomonas* was the least abundant  
168 taxonomic group present, also seen when individual subjects where analyzed (Fig. S4). Other  
169 less abundant phyla included *Verrucomicrobia* and within the *Proteobacteria*, the  
170 *Alphaproteobacteria* and *Epsilonproteobacteria* classes.

### 171 **The human URT microbiome is distributed into distinct ecostates due to IAV infection**

172 Due to the dynamic nature of the human URT microbiome during IAV infection, we  
173 hypothesized that infection perturbs the microbiome structure resulting in distinct signature  
174 microbiomes that differentiate infected from uninfected individuals. Thus, we used the Infinite  
175 Dirichlet-multinomial Mixture Model (iDMM) (21), which is an extension of the Dirichlet-  
176 multinomial mixture model (DMM) (22) that helps understand and interpret taxon abundance



177 data by adding statistical validation if a taxa is associated with a given case-control condition.  
178 This is an un-supervised clustering method that applies Bayesian statistics to quantitatively  
179 assess the data and accurately capture the features that are present. Essentially, given a set of  
180 subsampled distributions, the iDMM model predicts the original number of full-size distributions  
181 together with their composition. The nonparametric nature of the iDMM model makes it ideal for  
182 understanding the complex ecological data in this study, where the original number of the  
183 sampled communities (known as ecostates) is unknown.

184 The iDMM model was run over 2000 iterations over all data points (33 patients at multiple time  
185 points), which collapsed the data into a total of four ecostates (Table 2). Plotting the mean of the  
186 likelihood ratio at each iteration showed that, 25 iterations into the analysis, the maximum  
187 likelihood ratio converges for the model. One of the four ecostates included all 127 uninfected  
188 data points (or the “healthy” ecostate) while the 146 infected data points were distributed across  
189 the three other ecostates (or “unhealthy” ecostates). Interestingly, a few patients moved from the  
190 “unhealthy” ecostates during acute influenza infection to the “healthy” ecostate in the later time  
191 points. This suggests that the human microbiome exhibits resilience but potentially a weak  
192 elasticity; however, this could be due to the lack of a precise temporal control of the time of  
193 infection.

194 We also identified a diagnostic OTU for each of these ecostates, which is the OTU with the  
195 highest posterior predictive probability in the ecostate and therefore drives the clustering. The  
196 iDMM analysis predicted the diagnostic OTU for the healthy ecostate to be Otu000008 which  
197 belongs to the *Flavobacteria* class (*Cloacibacterium*), with a posterior predictive probability of  
198 0.08, followed by Otu000010 (*Corynebacterium\_1*) and Otu000013 (*Comamonadaceae*),  
199 belonging to the class Actinobacteria and Betaproteobacteria, respectively (Table 2). For the

200 “unhealthy” ecostates, Otu000003, Otu000004 and Otu000002 were diagnostic for Ecostate 1, 2  
201 and 3 respectively (Table 2). Ecostate 1 had the largest number of infected data points (114),  
202 followed by Ecostate 3 (20) and Ecostate 2 (9). Otu000003 and Otu000002 belong to the  
203 *Pseudomonadaceae* family (the latter being an unclassified *Pseudomonadaceae*), with relatively  
204 high posterior probabilities associated with each of them (Table 2). Otu000004 belonged to the  
205 *Actinobacteria* class and was the diagnostic OTU for Ecostate 2 with 9 infected data points.  
206 Remarkably, the diagnostic OTUs for all four ecostates for the human samples are also among  
207 the first ten most abundant OTUs for the data.

208 A random forest analysis was also used to identify predictive features in the data. The method we  
209 developed iterates through unique random forest models (each seeded with a different random  
210 state) and attempts to fit the model to a random subset of the data with five samples removed  
211 from the training set, (see Materials and Methods). If the model could accurately predict all five  
212 of the omitted samples during the cross-validation step, then its feature importance vector (mean  
213 decrease gini index) including weights for every OTU’s predictive capacity was collected. The  
214 results from the random forest classification aligned with our diagnostic iDMM OTU prediction  
215 in the human samples (Table S4). The analysis showed Otu000002 (unclassified  
216 *Pseudomonadales*) to be the most predictive of the IAV-infected samples, followed by  
217 Otu000001 (*Rhizobiales*) and Otu000003 (*Pseudomonas*) with a maximum accuracy of 71%.  
218 When we examined the taxonomy of Otu000001 in detail, it was classified with 100%  
219 confidence down to Genus *Ochrobactrum*, at which point the read length is unable to  
220 differentiate the species any further. Nevertheless, the actual OTU sequence is 100% identical to  
221 *Ochrobactrum anthropi*, an opportunistic human pathogen (23-25). Similarly, the in depth  
222 analyzes of Otu000006 identified the taxonomy of this OTU as uncultivated lineages of

223 Rhodanobacter, which have also been previously associated with human respiratory tract  
224 microbiomes (26). Comparison with our negative controls confirmed that these were not  
225 contaminants and supported the notion that Ochrobactrum was also diagnostic for the infection  
226 state in humans, which is likely to be consistent with the presence of *O. anthropii* or similar  
227 opportunistic species.

228

### 229 **Influenza virus infection modulates the microbiome structure of the URT in ferrets**

230 We hypothesized that IAV infection in ferrets will result in the clustering of microbiomes  
231 according to infection status, as observed during IAV infection in humans. Therefore, using the  
232 well-established ferret model of IAV infection, we designed a longitudinal study resembling the  
233 clinical specimens obtained from human patients to obtain nasal wash samples from infected  
234 animals. We collect nasal washes from 7 uninfected ferrets and 7 ferrets infected with the  
235 A/Netherlands/602/2009 (H1N1) pandemic strain, at 0, 1, 3, 5, 7 and 14 days post infection  
236 (dpi). The dynamics and relative abundances of bacteria in the URT microbiome were examined  
237 by pyrosequencing of the V1-V3 region of the 16S rRNA using similar thresholds for length and  
238 expected error as were chosen for the human data. A total of 649,440 reads clustered into 259  
239 (OTUs) with 79% of reads mapping (Table 1). As before, the count abundance data for the OTUs  
240 was normalized and the low abundance taxa were filtered out from the count data. Principal  
241 Coordinates Analysis (PCoA) of beta diversity between the healthy and IAV infected groups  
242 demonstrated variability consistent with the virus perturbing and modulating the microbiome  
243 structure (Fig. 3). Infection status strongly influenced the ordination of the samples as measured  
244 by the Bray-Curtis beta-diversity metric ( $R=0.503$ ,  $p$ -value  $< 0.001$ ). The IAV-negative and  
245 IAV-positive ferret microbial communities formed discrete clusters, while samples from the IAV

246 infected animals showed divergence from each other (Fig. 3). By the final time point, day 14, the  
247 microbiome of infected ferrets (light blue) was more similar to the Day 0 samples (lavender) and  
248 those of the uninfected controls (dark blue).

249  
250 Quantitative metrics of diversity were used to compare the microbiomes of influenza infected  
251 and control ferrets. Beta diversity distance analyses (Fig. S5) demonstrated that ferret  
252 microbiomes had higher diversity between infection states than within them. Student's two  
253 sample two-sided t-tests confirmed that the diversity between the two states (infected and  
254 uninfected) was statistically significant, with the microbiomes of infected ferrets being more  
255 diverse (Table S5). The t-statistic for the "All within infection" versus "All between infection"  
256 was -29.1592 corresponding to a Bonferroni-corrected parametric p-value of 1.90e-166 (Table  
257 S5). The PCoA and statistical analyses showed that infected ferrets have a far more dynamic  
258 URT microbiome than that of the uninfected group. We note that the "healthy" baseline  
259 experiments were not conducted at the same time and some divergence of the microbiomes was  
260 expected given the high level of personalization, and that ferrets are outbred. Remarkably, 4/7  
261 T=0 time points and 7/7 t=14 time points converged to the "healthy" microbiome from an  
262 independent experiment. Overall, the quantitative examination revealed that the range for  
263 infection-associated beta diversity was much lower in the ferret samples than it was from human  
264 clinical samples.

265  
266 **IAV infection induces temporal changes in the structure of the ferret URT microbiome**  
267 To assess the correlation of clinical symptoms overtime during acute IAV infection, we  
268 monitored the body weight of all ferrets from 0 to 14 dpi, which demonstrated a clear weight loss

269 among the infected animals (Fig. 4A). As expected, the maximum weight loss coincided with  
270 peak IAV titer from 3 to 5 dpi, and recovery in body weight correlated with the lack of  
271 detectable virus after day 7 (Fig. 4B). To better visualize the temporal trajectory of the ferret  
272 microbiome, the community composition for one representative influenza-infected and one  
273 uninfected ferret (ferret\_595 and ferret\_592, respectively) were examined with regards to their  
274 taxonomic profiles across six different time points (Fig. 4C and 4D). At the order level, the IAV-  
275 infected ferrets exhibited *Pseudomonadales* abundance at days 5 and 7 dpi (Fig. 4C-F), which  
276 correlated with maximal weight loss and peak viral titers (Fig. 4A and B), suggesting the direct  
277 or indirect influence of the infection on the microbiome. A few of the less-abundant phyla  
278 included *Actinobacteria* and *Firmicutes* (Fig. S6). The abundance of *Pseudomonas* decreased  
279 over time in the infected ferrets, reaching the basal abundance found in healthy ferrets 14 dpi.  
280 For the uninfected ferrets, the microbiomes were more stable and *Clostridiales* was the most  
281 abundant taxonomic group, followed by *Lactobacillales* (light blue). *Pseudomonadales* were  
282 among the least abundant taxonomic group in the uninfected controls (Fig. 4D). This was also  
283 observed when we analyzed the microbiome abundance of each individual animal in both  
284 infected and uninfected groups (Fig. S7). These results demonstrate that IAV infection induces a  
285 dynamic modulation of the microbiome structure in the URT of ferrets, which correlated with  
286 viral replication and pathogenesis. However, our data also suggests that the basal levels could be  
287 reestablished upon viral clearance, as observed in some human samples.

288

### 289 **IAV infection differentiates the ferret URT microbiome structure into defined ecostates**

290 Since the timing of infection was controlled in the ferret experiment, we hypothesized that upon  
291 infection the microbiome structure would be ordered into more defined ecostates for the infected

292 and uninfected animals. Hence, we run the iDMM model over 1000 iterations, which collapsed  
293 the data into two ecostates. The mean of the likelihood ratio at each iteration converged 70  
294 iterations into the analysis, splitting into two ecostates until the last iteration. Of interest, one of  
295 the two ecostates was comprised of all the uninfected data points (or the “healthy” ecostate)  
296 while the other contained most of the influenza infected data points (the “unhealthy” ecostate,  
297 Table 2). There were notable exceptions; despite the perturbation caused by the infection, all Day  
298 14 samples in the infected cohort moved from the “unhealthy” ecostate to the “healthy” ecostate,  
299 which is also shown in the ordination plot (Fig. 3). The healthy ecostate also contained a few of  
300 the earlier data points (Day 0 and Day 1) of the influenza-infected cohort, indicating a temporal  
301 lag in changes to the ferret microbiome at those time points when the IAV titer was submaximal  
302 (Fig. 4B).

303 The iDMM analysis for ferrets predicted the diagnostic OTU for the “unhealthy” ecostate to be  
304 Otu000004 that belonged to the *Pseudomonadales* order, with a posterior predictive probability  
305 of 0.11 (Table 3), followed by Otu000003 with the next highest predictive probability of 0.08,  
306 belonging more specifically to the *Pseudomonas* genus (Fig. S6). This is consistent with the  
307 qualitative taxonomic profiling (Fig. 4). For the “healthy” ecostate, Otu000001, which belongs to  
308 the *Clostridia* family, was the diagnostic OTU with a posterior predictive probability of 0.19  
309 (Table 3). The posterior probabilities for each taxon were calculated within each sample by  
310 observing the fraction of simulated samples with more counts than the observed value. The  
311 probabilities associated with the diagnostic OTUs can be thought in terms of being relative to all  
312 taxa present. Similar to the human data, the diagnostic OTUs for both ecostates are among the  
313 ten most abundant OTUs for the data (Fig. S6). Remarkably, this was also confirmed when the  
314 microbiome for all ferrets from both infected and uninfected groups was analyzed individually

315 (Fig. S7), which indicates that *Pseudomonadales* are not only predictive of the unhealthy  
316 ecostate but also undergo the greatest temporal dynamic change during IAV infection. This was  
317 confirmed when alpha diversity analyses were conducted, which showed a drastic decrease in  
318 diversity by day 7 (Fig. S8). The results from the random forest analysis aligned well with the  
319 iDMM diagnostic OTU prediction in that Otu000004 (*Pseudomonadales*) was the most  
320 predictive attribute for the samples from IAV-infected ferrets, followed by Otu000028  
321 (*Enterobacteriaceae*) and Otu000017 (*Bacillales*), with a maximum accuracy of 96% (Table S6).  
322 Altogether, these data indicates that IAV infection results in a nasal bloom of multiple  
323 *Pseudomonadales* in the ferrets, displacing the *Clostridia* associated with the “healthy” and  
324 stable ecostate.

## 325 **Discussion**

326 This longitudinal study describes taxonomic microbiome population dynamics in the upper  
327 respiratory tract of humans and ferrets during IAV infection. Given the unequivocal association  
328 between viral and bacterial co-infection and influenza disease severity, there is a pressing need to  
329 better understand how perturbation of the host microbiome correlates with viral infections that  
330 facilitate opportunistic co-infections. The nature of the 16S sequencing approach taken, that is a  
331 loci-based population survey, means that we can address taxonomy-centric ecological principles  
332 of disturbance and resilience (27, 28) in the URT microbiome. Our results strongly suggest that  
333 the core URT microbiome is perturbed by IAV infection via direct and uncharacterized indirect  
334 processes, which may in turn might facilitate co-infections with bacterial pathogens causing  
335 increased hospitalizations and morbidity associated with IAV infection. Additionally, the results  
336 provide a clear approach for the design of future studies explicitly examining the mechanistic  
337 links between IAV and bacterial co-infection, along with the development of therapeutic  
338 treatments aimed at the microbiome as a community.

339 Without disturbance or perturbation, the URT microbiome was stable in both uninfected humans  
340 and ferrets. IAV does not directly infect any microbiome constituents, yet infection disturbs the  
341 healthy-state microbiome in both hosts in a statistically robust manner. The microbiomes of  
342 infected (unhealthy) individuals or animals were quite different from each other (Fig. 4, 2 and  
343 Fig. S2, S3, S5 and S6). However, in both hosts, unhealthy microbiomes were divergent from the  
344 healthy microbiomes and numerous community assemblies were possible in the unhealthy state.  
345 This is a clear demonstration of the Anna Karenina principle (29), restated as “all healthy  
346 microbiomes are the same, while unhealthy microbiomes are unique.” This high diversity of  
347 unhealthy microbiomes during early stages of acute infection is consistent with earlier studies



348 (8), but here we demonstrate specifically that it can occur as a consequence of an indirect  
349 disturbance such as IAV infection. We propose that the disturbance of the healthy URT  
350 microbiome creates transient ecological niches for opportunistic bacterial pathogens. How viral  
351 infection induces a disturbance in the microbiome requires further assessment. Nevertheless, the  
352 host antiviral responses such as the induction of interferon during IAV infection, could  
353 contribute to the perturbation of the microbiome in a dynamic manner, though this requires host  
354 and microbiome metatranscriptomics or metaproteomics measurements in controlled  
355 experiments focused at the onset of infection. Nevertheless, maximum disturbance correlated  
356 with maximum viral loads and weight loss in the ferret model, which suggests a close  
357 relationship between active infection, disease and disturbance of the microbiome, with kinetics  
358 that are similar to the antiviral response induced during IAV infection (30).

359 The sole statistical exception to the high community diversity of infected microbiomes was the  
360 increased relative abundance of *Pseudomonadales*, regardless of age, sex, antibiotic treatment, or  
361 even host organism. Oddly enough in humans, no significant influence of the host type (age and  
362 sex) or behavior (antibiotic usage) was observed on the temporal nature of the microbiome  
363 elasticity, and more statistical power would be needed to draw any further robust associations  
364 from the data. Yet, the “bloom” of *Pseudomonadales* is consistent with previous reports in  
365 H1N1-infected patients (9, 15, 31, 32). In our study, *Pseudomonadales* are present in relatively  
366 low proportions in the healthy microbiome of these host organisms. Therefore, their “bloom”  
367 might be due to a more hostile environment for the other taxa or perhaps a more hospitable  
368 environment for the *Pseudomonadales*, making this an excellent candidate for future strain  
369 isolation, genome sequencing, and transcriptional profiling. The increased abundance of  
370 *Pseudomonadales* and the decreased relative abundance of *Clostridiales* and *Actinobacteria* in

371 the infected cohorts suggest a potential use for probiotic treatments capable of modulating the  
372 microbiome back into the healthy ecostate (33). Such a treatment would be homologous to those  
373 proposed for perturbing or restoring the gut microbiome (34). Understanding how and why  
374 *Pseudomonadales* succeed after disturbance will provide valuable information for conducting  
375 future microbiome centric URT studies in a controlled setting. It should be noted that the  
376 blooming *Pseudomonads* are not *P. aeruginosa*, instead a variety of other related species within  
377 the genera, and understanding their functional potential and role requires shotgun metagenomics  
378 analyses for more detailed phylogenetic and functional profiling.

379 In addition, in humans secondary *Pseudomonas* infections have been extensively described  
380 before, and *Pseudomonas* infections have been specifically linked to nosocomial infections as a  
381 result respiratory support treatments in hospital settings (35-39). It is currently unknown whether  
382 infection with other respiratory viruses can also induce the modulation of the URT microbiome,  
383 however; since severe viral infections often require respiratory support, including intubation, it is  
384 likely that co-infection with pathogens such as the *Pseudomonadales* could actually be favored  
385 due to previous perturbations of the microbiome. Hence, additional associative studies to  
386 elucidate factors that modulate the temporal change of the microbiome structure could also aid in  
387 understanding the factors that promote or support secondary bacterial colonization during severe  
388 respiratory viral infections.

389 In the ferret model, there is a clear demonstration of ecological resilience in the URT  
390 microbiome; namely a return to the original community after disturbance, a phenomenon also  
391 observed, albeit less clearly, in the human samples, which had an unknown and likely more  
392 diverse ecostate prior to infection. Similar observations have been reported in the human gut  
393 microbiome after the massive disturbance associated with antibiotic treatment (27), though our

394 findings expands it to the URT and the indirect effects of the IAV infection. The controlled  
395 experiments with ferrets resulted in near complete recovery. Human URT microbiomes do not  
396 unequivocally show a return to the health state, but in several patients, the microbiome returned  
397 to the healthy ecostate. Although it is tempting to suggest that the ferret microbiome might have  
398 greater elasticity (i.e. less time required for demonstration of resilience), there are multiple  
399 potential reasons for the discrepancy between ferrets and humans. Considering metabolic rate  
400 relative to organism size, the ferret may recover at a more rapid rate simply due to a higher  
401 metabolism. More pertinently, the human cohort has an undetermined infection date, were  
402 infected by different viral strains (and viral variants as determined by whole IAV genome  
403 sequences) and had a selection bias towards phenotypically responsive patients (e.g.  
404 symptomatic hospitalized patients), where zero time (Day 0) was the first hospital visit. Beyond  
405 the potential differences in absolute temporal trends in microbiome resilience and elasticity, the  
406 human and ferret microbiomes share similar trends at the ecosystem and individual taxon level  
407 that warrant further experimentation. The results here provide an experimental baseline for  
408 examining both predictive and therapeutic intervention focused experiments in the ferret model  
409 system. For example, the presented hypothesis that IAV driven microbiome disturbance  
410 increases the propensity for bacterial pathogen co-infection can be robustly tested by bi-partite  
411 exposures to viral, and then bacterial pathogens. The effects of lifestyle (diet, smoking, exercise)  
412 and abiotic influences (humidity, temperature) on the microbiome and its resilience should also  
413 be examined, particularly with regards to temporal dynamics of microbiome disturbance and  
414 recovery. Potential therapeutic approaches involve thwarting the associated threat of  
415 opportunistic bacterial pathogens or interventions focused on the bloom of *Pseudomonas*, where  
416 probiotic treatments could be explored to maintain the homeostasis as seen in the healthy

417 individuals. Our results are especially relevant in the context of secondary bacterial infections  
418 following primary infection with IAV (40). Multiple studies, including this one, have now shown  
419 that a subset of the taxa that are most frequently associated with secondary infections have  
420 increased relative abundance during IAV infection. It is possible that such outcomes could be  
421 reduced by modulating the host immune response during IAV infection (17). Reducing the high  
422 morbidity and mortality rates associated with such secondary infections would improve quality  
423 of life and longevity while simultaneously reducing healthcare costs (35, 41, 42).

424

## 425 **Materials and Methods**

### 426 **Human sample collection and study design**

427 Patient clinical–epidemiological data, along with nasopharyngeal swabs were collected after  
428 informed written consent was obtained under protocol 11-116, reviewed and approved by the  
429 Scientific Ethics Committee of the School of Medicine at Pontificia Universidad Catolica de  
430 Chile (PUC) before the start of sample collection. Between July 2011 and November 2012, a  
431 total of 146 nasopharyngeal swabs samples were collected from 30 hospitalized patients in  
432 Santiago, Chile, diagnosed with influenza-like illness (ILI). Of the 30 patients in the study, 28  
433 were confirmed and subtyped as H1N1pdm09 or H3N2 Influenza through RT-PCR by Clinical  
434 Virology Laboratory at PUC. The remaining 2 patients could not be confirmed as influenza  
435 positive by qRT-PCR, RT-PCR and/or the hemagglutination inhibition (HI) assay, but still  
436 displayed the perturbation in their microbiome so they were included in the analyses. Between  
437 one and six samples from the acute phase of infection were taken from each patient, together  
438 with a sample up to 22 days post diagnosis (convalescence phase or healthy baseline) from most  
439 of individuals. Control samples from 22 healthy individuals, confirmed as negative against

440 influenza A virus and 13 other common respiratory viruses, were taken with the same criteria in  
441 March to June of 2014. Epidemiological history, signs and symptoms, other diagnostics and  
442 treatments of each patient were also collected during hospitalization as detailed in Table S3.  
443 Furthermore, 96.4% of patients received oseltamivir antiviral treatment and 89.3% received  
444 antibiotics originating from the families of the fluoroquinolones (levofloxacin, moxifloxacin or  
445 ciprofloxacin), 3rd generation cephalosporins (ceftriaxone or cefepime), carbapenems  
446 (meropenem or imipenem), metronidazole, cotrimoxazole or vancomycin. These treatments  
447 were supplied in a combination of 5 (4% of patients), 4 (8%), 3 (12%), 2 (40%) or one (36%)  
448 antibiotics in a complete treatment (at least seven days) or less. Severe infection criteria were  
449 established in accordance with the hospitalization due to influenza and/or derivation to Critical  
450 Care Unit (which involves oxygen support or mechanical ventilation and/or vasoactive drug  
451 administration) after symptoms onset. The microbiome data analyzed were obtained from the  
452 nasopharyngeal swabs of 33 infected subjects (14 male and 19 female), ages ranging from one  
453 year to 76 years, for a total of 146 samples. The naming convention of influenza A viruses  
454 detected from patients are as follows: A/Santiago/pxdy/2011 or A/Santiago/pxdy/2012 (p=patient  
455 and d=day). The negative controls analyzed in the study were nasopharyngeal swabs taken from  
456 22 healthy patients (10 males and 12 females), most taken at all 6 time points (1, 2, 3, 5, 8 and 28  
457 dpi), for a total of 127 samples, which were negative for influenza and other respiratory  
458 infections.

459

#### 460 **Ferret infection and sample collection**

461 The animal experiments described here were performed under protocols approved by the Icahn  
462 School of Medicine at Mount Sinai Institutional Animal Care and Use Committee, adhering

463 strictly to the NIH Guide for the Care and Use of Laboratory Animals. Six months old female  
464 ferrets (*Mustela putorius furo*) were confirmed to be seronegative against circulating H1N1,  
465 H3N2 and B influenza viruses before they purchased from Triple F Farms. Throughout the  
466 experiment the animals were housed individually in PlasLabs poultry incubators with access to  
467 food and water *ad libitum*. All infections and nasal wash samples were done on ferrets  
468 anesthetized with ketamine (25 mg/kg) and xylazine (2mg/kg) intramuscularly. A detailed time  
469 point study was conducted in ferrets infected with  $1 \times 10^6$  plaque forming units diluted in a final  
470 volume of 5.0 ml of sterile PBS per animal of the A/Netherlands/602/2009 H1N1 pandemic  
471 strain through intranasal inoculation. Control animals were mock infected only with 0.5 ml of  
472 sterile PBS. Then nasal wash samples were taken from the 7 uninfected and 7 infected animals.  
473 To study the effect of IAV infection on the URT microbiome, samples were taken at 6 different  
474 timepoints: on day 0 (1 hr post inoculation) and then on days 1, 3, 5, 7 and 14 post infection  
475 (dpi). Body weights were obtained for 14 consecutive days, and viral titers were determined by  
476 plaque assay in MDCK cells as previously described (43) for the first 7 dpi.

477

478

#### 479 **Sample processing and sequence analyses**

480 All bacterial genomic DNA (gDNA) extractions were performed using the Qiagen All Prep kit  
481 and were subjected to 16S amplification using the HMP 16S sequencing protocol and the  
482 amplicons were sequenced using the Roche 454 Titanium pipeline (44). Appropriate positive and  
483 negative controls from amplification were also included. The V1-V3 hypervariable regions were  
484 amplified for 16S profiling (forward primer: 27F 5'- AGAGTTTGATCCTGGCTCAG-3' and  
485 reverse primer: 534R 5'- ATTACCGCGGCTGCTGG-3') of the 16S ribosomal RNA gene.

486

## 487 **Data Analysis**

488 Reads were de-multiplexed according to barcodes followed by trimming of both barcodes and  
489 adapter sequences. Following the initial processing of the sequence data, sequences were  
490 combined, dereplicated and aligned in mothur (version 1.36.1 (45)) using the SILVA template  
491 (46) (SSURef\_NR99\_123) and the sequences were organized into clusters of representative  
492 sequences based on taxonomy called Operational Taxonomic Units (OTU) using the UPARSE  
493 pipeline (47). In the ferrets, all except two libraries generated more than 3000 reads per sample.  
494 A total of 649,440 sequences were subsequently clustered into 259 OTUs with a sequence  
495 similarity threshold of 97% (45), a length threshold of 250 bp and an expected error threshold of  
496 0.15. For human samples, the distribution of reads per sample was much more uneven. A total of  
497 2,342,992 sequences were sorted into 707 OTUs, using the same thresholds as above and the  
498 same downstream filtering of the OTUs and samples was performed in a similar manner. Initial  
499 filtering of the samples ensured discarding samples containing less than 5 sequences. Libraries  
500 were normalized using metagenomeSeq's cumulative sum scaling method (48) to account for  
501 library size acting as a confounding factor for the beta diversity analysis. In addition to  
502 discarding singletons, OTUs that were observed fewer than 5 times in the count data were also  
503 filtered out to avoid the inflation of any contaminants that might skew the diversity estimates.

504

## 505 **Informatics**

506 Beta diversity metrics were calculated across all samples using the Bray-Curtis dissimilarity  
507 index and overall trends in the community composition for ferrets and humans on the basis of

508 presence or absence of the flu infection were explored using Principal Coordinates Analysis  
509 (PCoA) in QIIME (49) (version 1.9.1) and then visualized in Emperor (50) (version 0.9.51).

510

511 Taxonomic classification of the samples was done by classifying the representative sequences  
512 from the OTUs using mothur and the SILVA database, with a confidence threshold of 97%. The  
513 relative abundances for the taxonomic profiles for each subject was calculated in QIIME using  
514 `summarize_taxa.py`. The visualization of the top ten most prevalent taxa for each of the  
515 organisms was done in R (version 3.2.2) using `dplyr` and `reshape2` to manipulate the data and  
516 `ggplot2` for generating the plots. Following the qualitative analysis of the data, we employed an  
517 infinite dimensional generalization of the multinomial Dirichlet mixture model (21) which tries  
518 to model the original set of communities from the input data with additional posterior predictive  
519 probabilities (PPD) for statistical cut offs. The model was executed over 1000 iterations for the  
520 ferret data and 2000 iterations for the human data since this parameter should increase with the  
521 number of samples present in the dataset. Scripts located at  
522 <https://github.com/jacobian1980/ecostates> were improved by introducing a seed in the beginning  
523 of the algorithm to improve the reproducibility of the model and optimized the community  
524 number based on the PPDs which compare empirically observed data with the data that would be  
525 expected if the DMM were the correct underlying model (51, 52). All downstream analyses with  
526 the communities, including exploration of community membership, were performed in R.  
527 Additionally, a diagnostic OTU was computed for each ecostate, or sampled community, which  
528 is the OTU with the highest posterior predictive probability in the ecostate and therefore drives  
529 the clustering. The quantitative portion of the analysis was supplemented by performing random  
530 forest classification on the data to confirm the diagnostic results using Scikit-Learn (version



531 0.18.1) in Python (version 3.5.2) from Continuum Analytics Anaconda Suite. The training  
532 dataset included: a  $(n \times m)$ -dimensional attribute matrix consisting of the relative abundance  
533 values for the OTUs and the samples, where  $n$  and  $m$  refer to the number of samples and the  
534 number of OTUs respectively, and a  $(n)$ -dimensional vector relating each observation to the 2  
535 experimental states (positive and negative for the virus). The average of the feature importance  
536 vectors from 20000 models that could accurately predict all 5 left-out samples (~85% accuracy)  
537 was computed to obtain a weight for each OTU's predictive capacity to classify the experimental  
538 state of each sample. The hyperparameters for the random forest model were 618 decision trees  
539 per forest, gini index as impurity criterion and the square root of the number of features (OTUs  
540 in this case) to use for each split in the decision tree.

541

542 **Data Availability:** Raw amplicon sequence reads for this study have been deposited to Sequence  
543 Read Archive (SRA) under accession number: SRP009696 [BioProject accession number:  
544 PRJNA76689] for the ferrets and accession numbers: SRP092459 [BioProject accession number:  
545 PRJNA240559] and SRP128464 [PRJNA240562] for the infected and uninfected human  
546 subjects respectively.

#### 547 **References and Notes:**

- 548 1. A. D. Iuliano *et al.*, Estimates of global seasonal influenza-associated respiratory  
549 mortality: a modelling study. *Lancet*, (2017).
- 550 2. N. P. Johnson, J. Mueller, Updating the accounts: global mortality of the 1918-1920  
551 "Spanish" influenza pandemic. *Bull Hist Med* **76**, 105-115 (2002).
- 552 3. J. F. Brundage, Interactions between influenza and bacterial respiratory pathogens:  
553 implications for pandemic preparedness. *Lancet Infect Dis* **6**, 303-312 (2006).
- 554 4. J. F. Brundage, G. D. Shanks, Deaths from bacterial pneumonia during 1918-19 influenza  
555 pandemic. *Emerg Infect Dis* **14**, 1193-1199 (2008).

- 556 5. D. M. Morens, J. K. Taubenberger, A. S. Fauci, Predominant role of bacterial pneumonia  
557 as a cause of death in pandemic influenza: implications for pandemic influenza  
558 preparedness. *J Infect Dis* **198**, 962-970 (2008).
- 559 6. C. C. Blyth *et al.*, The impact of bacterial and viral co-infection in severe influenza.  
560 *Influenza Other Respir Viruses* **7**, 168-176 (2013).
- 561 7. N. S. Shah *et al.*, Bacterial and viral co-infections complicating severe influenza:  
562 Incidence and impact among 507 U.S. patients, 2013-14. *J Clin Virol* **80**, 12-19 (2016).
- 563 8. E. S. Charlson *et al.*, Topographical continuity of bacterial populations in the healthy  
564 human respiratory tract. *Am J Respir Crit Care Med* **184**, 957-963 (2011).
- 565 9. Y. Tarabichi *et al.*, The administration of intranasal live attenuated influenza vaccine  
566 induces changes in the nasal microbiota and nasal epithelium gene expression profiles.  
567 *Microbiome* **3**, 74 (2015).
- 568 10. S. Langevin *et al.*, Early nasopharyngeal microbial signature associated with severe  
569 influenza in children: a retrospective pilot study. *J Gen Virol*, (2017).
- 570 11. Z. Gao, Y. Kang, J. Yu, L. Ren, Human pharyngeal microbiome may play a protective  
571 role in respiratory tract infections. *Genomics Proteomics Bioinformatics* **12**, 144-150  
572 (2014).
- 573 12. Y. J. Huang, S. V. Lynch, The emerging relationship between the airway microbiota and  
574 chronic respiratory disease: clinical implications. *Expert Rev Respir Med* **5**, 809-821  
575 (2011).
- 576 13. P. J. Planet *et al.*, Lambda Interferon Restructures the Nasal Microbiome and Increases  
577 Susceptibility to Staphylococcus aureus Superinfection. *MBio* **7**, e01939-01915 (2016).
- 578 14. F. J. Whelan *et al.*, The loss of topography in the microbial communities of the upper  
579 respiratory tract in the elderly. *Ann Am Thorac Soc* **11**, 513-521 (2014).
- 580 15. B. Chaban *et al.*, Characterization of the upper respiratory tract microbiomes of patients  
581 with pandemic H1N1 influenza. *PLoS One* **8**, e69559 (2013).
- 582 16. T. Ichinohe *et al.*, Microbiota regulates immune defense against respiratory tract  
583 influenza A virus infection. *Proc Natl Acad Sci U S A* **108**, 5354-5359 (2011).
- 584 17. J. Wang *et al.*, Bacterial colonization dampens influenza-mediated acute lung injury via  
585 induction of M2 alveolar macrophages. *Nat Commun* **4**, 2106 (2013).
- 586 18. S. Wu *et al.*, Microbiota regulates the TLR7 signaling pathway against respiratory tract  
587 influenza A virus infection. *Curr Microbiol* **67**, 414-422 (2013).
- 588 19. J. A. Belser, A. M. Eckert, T. M. Tumpey, T. R. Maines, Complexities in Ferret Influenza  
589 Virus Pathogenesis and Transmission Models. *Microbiol Mol Biol Rev* **80**, 733-744  
590 (2016).
- 591 20. J. A. Belser, J. M. Katz, T. M. Tumpey, The ferret as a model organism to study  
592 influenza A virus infection. *Disease Models & Mechanisms* **4**, 575-579 (2011).
- 593 21. J. D. O'Brien, N. Record, P. Countway, The power and pitfalls of Dirichlet-multinomial  
594 mixture models for ecological count data. *bioRxiv*, (2016).
- 595 22. I. Holmes, K. Harris, C. Quince, Dirichlet Multinomial Mixtures: Generative Models for  
596 Microbial Metagenomics. *PLOS ONE* **7**, e30126 (2012).
- 597 23. M. Menuet *et al.*, First isolation of two colistin-resistant emerging pathogens,  
598 *Brevundimonas diminuta* and *Ochrobactrum anthropi*, in a woman with cystic fibrosis: a  
599 case report. *J Med Case Rep* **2**, 373 (2008).
- 600 24. Y. J. Huang *et al.*, A persistent and diverse airway microbiota present during chronic  
601 obstructive pulmonary disease exacerbations. *OMICS* **14**, 9-59 (2010).

- 602 25. R. P. Dickson, J. R. Erb-Downward, G. B. Huffnagle, Homeostasis and its disruption in  
603 the lung microbiome. *Am J Physiol Lung Cell Mol Physiol* **309**, L1047-1055 (2015).
- 604 26. A. A. Heirali *et al.*, The effects of inhaled aztreonam on the cystic fibrosis lung  
605 microbiome. *Microbiome* **5**, 51 (2017).
- 606 27. D. A. Relman, The human microbiome: ecosystem resilience and health. *Nutrition*  
607 *reviews* **70**, S2-S9 (2012).
- 608 28. B. Walker, C. S. Holling, S. R. Carpenter, A. Kinzig, Resilience, adaptability, and  
609 transformability in social-ecological systems. *Ecology and Society* **9**, 5 (2004).
- 610 29. J. R. Zaneveld, R. McMinds, R. Vega Thurber, Stress and stability: applying the Anna  
611 Karenina principle to animal microbiomes. *Nature Microbiology* **2**, 17121 (2017).
- 612 30. M. J. Killip, E. Fodor, R. E. Randall, Influenza virus activation of the interferon system.  
613 *Virus Res* **209**, 11-22 (2015).
- 614 31. E. Y. Klein *et al.*, The frequency of influenza and bacterial coinfection: a systematic  
615 review and meta-analysis. *Influenza Other Respir Viruses* **10**, 394-403 (2016).
- 616 32. R. K. Leung *et al.*, Modulation of potential respiratory pathogens by pH1N1 viral  
617 infection. *Clin Microbiol Infect* **19**, 930-935 (2013).
- 618 33. H. W. Chen *et al.*, Nasal commensal *Staphylococcus epidermidis* counteracts influenza  
619 virus. *Sci Rep* **6**, 27870 (2016).
- 620 34. J. K. Spinler *et al.*, From prediction to function using evolutionary genomics: human-  
621 specific ecotypes of *Lactobacillus reuteri* have diverse probiotic functions. *Genome Biol*  
622 *Evol* **6**, 1772-1789 (2014).
- 623 35. D. E. Morris, D. W. Cleary, S. C. Clarke, Secondary Bacterial Infections Associated with  
624 Influenza Pandemics. *Front Microbiol* **8**, 1041 (2017).
- 625 36. A. Hotterbeekx *et al.*, The endotracheal tube microbiome associated with *Pseudomonas*  
626 *aeruginosa* or *Staphylococcus epidermidis*. *Sci Rep* **6**, 36507 (2016).
- 627 37. J. Rello, Bench-to bedside review: Therapeutic options and issues in the management of  
628 ventilator-associated bacterial pneumonia. *Crit Care* **9**, 259-265 (2005).
- 629 38. Q. Lu *et al.*, *Pseudomonas aeruginosa* serotypes in nosocomial pneumonia: prevalence  
630 and clinical outcomes. *Crit Care* **18**, R17 (2014).
- 631 39. G. Hoffken, M. S. Niederman, Nosocomial pneumonia: the importance of a de-escalating  
632 strategy for antibiotic treatment of pneumonia in the ICU. *Chest* **122**, 2183-2196 (2002).
- 633 40. N. Sharma-Chawla *et al.*, Influenza A Virus Infection Predisposes Hosts to Secondary  
634 Infection with Different *Streptococcus pneumoniae* Serotypes with Similar Outcome but  
635 Serotype-Specific Manifestation. *Infect Immun* **84**, 3445-3457 (2016).
- 636 41. R. K. Gupta, R. George, J. S. Nguyen-Van-Tam, Bacterial pneumonia and pandemic  
637 influenza planning. *Emerg Infect Dis* **14**, 1187-1192 (2008).
- 638 42. J. C. Kash, J. K. Taubenberger, The role of viral, host, and secondary bacterial factors in  
639 influenza pathogenesis. *Am J Pathol* **185**, 1528-1536 (2015).
- 640 43. B. Manicassamy *et al.*, Protection of mice against lethal challenge with 2009 H1N1  
641 influenza A virus by 1918-like and classical swine H1N1 based vaccines. *PLoS Pathog* **6**,  
642 e1000745 (2010).
- 643 44. M. Margulies *et al.*, Genome sequencing in microfabricated high-density picolitre  
644 reactors. *Nature* **437**, 376-380 (2005).
- 645 45. P. D. Schloss *et al.*, Introducing mothur: open-source, platform-independent, community-  
646 supported software for describing and comparing microbial communities. *Appl Environ*  
647 *Microbiol* **75**, 7537-7541 (2009).

- 648 46. C. Quast *et al.*, The SILVA ribosomal RNA gene database project: improved data  
649 processing and web-based tools. *Nucleic Acids Res* **41**, D590-596 (2013).
- 650 47. R. C. Edgar, UPARSE: highly accurate OTU sequences from microbial amplicon reads.  
651 *Nat Methods* **10**, 996-998 (2013).
- 652 48. J. N. Paulson, O. C. Stine, H. C. Bravo, M. Pop, Differential abundance analysis for  
653 microbial marker-gene surveys. *Nature Methods* **10**, 1200 (2013).
- 654 49. J. G. Caporaso *et al.*, QIIME allows analysis of high-throughput community sequencing  
655 data. *Nat Methods* **7**, 335-336 (2010).
- 656 50. Y. Vazquez-Baeza, M. Pirrung, A. Gonzalez, R. Knight, EMPeror: a tool for visualizing  
657 high-throughput microbial community data. *Gigascience* **2**, 16 (2013).
- 658 51. A. Gelman, X.-L. Meng, H. Stern, POSTERIOR PREDICTIVE ASSESSMENT OF  
659 MODEL FITNESS VIA REALIZED DISCREPANCIES. *Statistica Sinica* **6**, 733-760  
660 (1996).
- 661 52. X.-L. Meng, Multiple-Imputation Inferences with Uncongenial Sources of Input. *Statist.*  
662 *Sci.* **9**, 538-558 (1994).

663

664 **Acknowledgements:**

665 The authors would like to thank research nurse Claudia Marco and the following clinical fellows  
666 and pediatricians that contributed to the recruitment of patients and the collection of samples  
667 used in this study: Marta Aravena, Catalina Gutierrez, Tania Lopez, Regina Perez and Cecilia  
668 Vizcaya from the Department of Pediatric Infectious Diseases and Immunology, Facultad de  
669 Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Funding: This project has  
670 been partly funded with federal funds from the National Institute of Allergy and Infectious  
671 Diseases, National Institutes of Health, Department of Health and Human Services under  
672 Contract Number HHNS272200900007C/ HHSN266200700010C and Grant Number  
673 U19AI110819, grants from the Comisión Nacional de Investigación Científica y Tecnológica  
674 (FONDECYT 1121172 and 1161791 to R.A.M.; and PIA ACT 1408 to R.A.M. and M.F.), and  
675 the Chilean Ministry of Economy, Development and Tourism (P09/016-F to R.A.M.). This study  
676 was also partially supported by CRIP (Center for Research in Influenza Pathogenesis), an NIAID  
677 funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract #  
678 HHSN272201400008C) and by NIAID grant U19AI135972 (to A.G.-S. and R.A.M.).

679

680 **Author Contributions:** D.K. and R.R. analyzed data, prepared illustrations, and wrote the  
681 manuscript. M.F. designed human cohort study, recruited patients, collected clinical metadata  
682 and wrote parts of the paper. G.S.T., B.E.P. carried out data analysis and wrote parts of the  
683 paper. A.B. carried out data analysis, prepared illustrations, and wrote parts of the paper. D.W.  
684 and B.M. obtained funding, designed and supervised experiments and analyzed data. S.D.  
685 supervised experiments and analyzed data. I.B. recruited patients and collected clinical metadata.  
686 R.A.H. performed sequencing experiments and metadata compilation. M.S., I.M., R.A.A.  
687 performed ferret experiments. I.S. performed data processing and analysis. K.E.N. Obtained

688 funding, supervised this study and wrote parts of the paper. A.G.S. conceived and supervised this  
689 study and wrote the manuscript. C.L.D. supervised this study, designed informatics analyses,  
690 analyzed data, prepared illustrations, and wrote the manuscript. R.A.M. obtained funding,  
691 conceived and supervised this study, designed and performed experiments, analyzed data,  
692 prepared illustrations, and wrote the manuscript.


693

694 **Competing Interests:** The authors declare no competing interests.

695


696

697 **Figures**



698


699 **Figure 1. Diversity of the URT microbiome of human patients infected with influenza A**  
700 **virus (IAV).** Beta diversity analysis for longitudinal nasopharyngeal swab samples obtained  
701 from healthy and IAV infected individuals. Principal coordinates analysis (PCoA) of Bray-Curtis  
702 distances was done for samples from humans, labeled as influenza positive in red (P, indicating  
703 data points with positive IAV qRT-PCR detection), influenza unknown in yellow (U, indicates  
704 time points from positive individuals that were below the qRT-PCR detection limits at different  
705 time points after the onset of symptoms) and uninfected samples in blue (Flu negative). The total  
706 variability explained by all three principal coordinates (PCs) is shown on the axes.



708 **Figure 2. Comprehensive taxonomic breakdown for IAV-free (left) and IAV-infected**  
709 **(right) human subjects.** The plot summarizes the relative taxonomic abundances at the class  
710 level for taxonomic groups that are present in greater than 5% of the samples (see legend below).  
711 Gammaproteobacteria (*Pseudomonas*, orange) bloom is prevalent among the infected patients  
712 (right), whereas Actinobacteria is the most abundant among healthy patients.

713






714

715 **Fig. 3: Diversity of the URT microbiome in ferrets during IAV infection.** Beta diversity  
716 analysis for longitudinal URT samples taken after experimental infection with the  
717 A/Netherlands/602/09 H1N1 strain (Infected) or in control animals. Principal coordinates  
718 analysis (PCoA) of Bray Curtis distances was performed for all samples. Data points for  
719 uninfected ferrets are in blue, the T=0 for the infected ferrets in lavender, the T=14 for infected  
720 ferrets in cyan, and all other infected time points are in red. The total variability explained by all  
721 three principal coordinates (PCs) is shown on the axes. Each group of ferret was composed of 7

722 animals.



723

724 **Fig. 4. Qualitative and quantitative representation of the temporal trajectory of the ferret**

725 **microbiome. (A) Percent body weights of groups of 7 ferrets mock inoculated (uninfected) or**

726 intranasally infected with  $1 \times 10^6$  pfu of influenza A/Neth/602/09 virus. Body weights were  
727 determined daily for 14 days, and are represented as the average percent body weight compared  
728 to the initial weight of each animal on the day of inoculation and error bars are the standard  
729 deviation for each time point. (B) Viral titers of nasal washes of ferrets infected with  $1 \times 10^6$  pfu  
730 of A/Neth/602/09 virus. Nasal washes were obtained on days 1, 3, 5 and 7 post infection and are  
731 represented as the average viral titer of 7 infected animals. Error bars indicate the standard  
732 deviation for each time point. (C-D) Comprehensive taxonomic breakdown of an influenza  
733 infected (C) and uninfected ferret (D), at different timepoints. Taxa abundance values for top ten  
734 most prevalent taxa at the order level for different timepoints (0 to 14 dpi). Only taxa labels with  
735 a confidence score of  $\geq 90\%$  were retained in the analysis. The remaining taxa are pooled into  
736 an additional taxon labeled "Other". (E-F) Average and standard deviation of the relative  
737 *Pseudomonas* abundance across all infected (E) and uninfected (F) ferrets (n=7 for each).

738 **TABLES**

739 **Table 1.** Summary statistics for amplicon-based sequencing of the V1-V3 region of the 16S  
740 rRNA gene.

	<b>Humans</b>	<b>Ferrets</b>
Total no. of samples <sup>a</sup>	273	86
Influenza negative subjects	22	7
Influenza positive subjects	33	7
Total no. of reads	2 342 992	649 440
Total no. of OTUs	707	259
No. of reads mapped to OTUs	2 151 233 (91.8%)	514 099 (79.2%)

741 a. All ferret and human samples were extracted from nasal washes and nasopharyngeal swabs, respectively, at several time points  
742 post infection.

743 **Table 2.** Diagnostic microbes for each ecostate from the 2000<sup>th</sup> iteration of the iDMM model for the  
 744 infected and uninfected humans. Number of iterations depends on the number of samples (273) present in  
 745 the data.

Ecostate	Final distribution <sup>a</sup>	Original sample distribution <sup>b</sup>	Diagnostic OTU	Probability associated <sup>c</sup>	Taxonomy
1 + 2 + 3 (Infected)	114	146	Otu000003	0.361568	Bacteria;Proteobacteria; Gammaproteobacteria;Pseudomonadales; Pseudomonadaceae;Pseudomonas
	9		Otu000004	0.4989514	Bacteria;Actinobacteria; Actinobacteria;Corynebacteriales; Corynebacteriaceae; Corynebacterium_1
	20		Otu000002	0.01584407	Bacteria;Proteobacteria; Gammaproteobacteria; Pseudomonadales;unclassified
4 (Healthy)	130	127	Otu000008	0.07636954	Bacteria;Bacteroidetes; Flavobacteriia;Flavobacteriales; Flavobacteriaceae;Cloacibacterium

746  
 747 a. Distribution of samples within ecostates after running the iDMM model.  
 748 b. Distribution of samples before running the iDMM model.  
 749 c. Bayesian posterior predictive probabilities associated with the diagnostic microbe, which is the highest probability for that  
 750 ecostate.

751 **Table 3.** Diagnostic microbes for each ecostate from the 1000<sup>th</sup> iteration of the iDMM model for  
 752 the ferret samples. Number of iterations depends on the total number of samples (84) present in  
 753 the data. All later time point ferrets (T14) return to the healthy ecostate (1).

Ecostate	Total samples	No. of samples <sup>a</sup>			Diagnostic OTU	Probability <sup>b</sup> associated	Taxonomy
		T14	[T7 + T5 + T3 + T1]	T0			
1 (Healthy)	<b>58</b> (42)	<b>14</b> (7)	<b>33</b> (28)	<b>11</b> (7)	Otu000001	0.1865749	Bacteria;Firmicutes; Clostridia;Clostridiales; Peptostreptococcaceae; Romboutsia
2 (Infected)	<b>26</b> (42)	<b>0</b> (7)	<b>23</b> (28)	<b>3</b> (7)	Otu000004	0.1112045	Bacteria;Proteobacteria; Gammaproteobacteria; Pseudomonadales; Moraxellaceae; Acinetobacter

754 a. No. of samples at final iteration for each time point in bold (original starting values in parentheses).

755 b. Bayesian posterior predictive probabilities associated with the microbe, which is the highest probability for that ecostate.

756 **Supplementary Materials:**

757

758 **Figure S1. Diversity distance analyses of the microbiome of infected and uninfected**  
759 **humans.**

760 **Figure S2. Relative abundance for the top ten bacterial families in the URT among infected**  
761 **and uninfected human subjects.**

762 **Figure S3. Comprehensive taxonomic breakdown for influenza-infected human subjects.**

763 **Figure S4. Comprehensive temporal taxonomic breakdown for 6 human subjects.**

764 **Figure S5. Diversity distance analyses of the microbiome of infected and uninfected ferrets.**

765 **Figure S6. Relative abundance for the top ten most prevalent bacterial families in the URT**  
766 **among infected and uninfected ferrets.**

767 **Figure S7. Comprehensive taxonomic breakdown for all 14 ferrets.**

768 **Table S1. Clinical-epidemiological characteristics of the hospitalized human patients**  
769 **diagnosed with Influenza A-like illness, and healthy controls.**

770 **Table S2. Two-sided Student's two sample t test results for human samples.**

771 **Table S3. Non-parametric multivariate analysis using Anosim and Adonis tests.**

772 **Table S4: Random forest analysis results for the human microbiomes.**

773 **Table S5. Two-sided Student's two sample t test results for ferrets.**

774 **Table S6. Random forest analysis results for the ferret microbiomes.**

775 **Supplemental information for**

776 **Microbiome disturbance and resilience dynamics of the upper respiratory**

777 **tract in response to influenza A virus infection in humans and ferrets**

778

779 Drishti Kaul<sup>1,8</sup>, Raveen Rathnasinghe<sup>2,8</sup>, Marcela Ferres<sup>2</sup>, Gene S. Tan<sup>1,3</sup>, Aldo Barrera<sup>2,4</sup>, Brett  
780 E. Pickett<sup>5</sup>, Barbara A. Methe<sup>5</sup>, Suman Das<sup>5</sup>, Isolda Budnik<sup>2</sup>, Rebecca Halpin<sup>5</sup>, David  
781 Wentworth<sup>5b</sup>, Mirco Schmolke<sup>6c</sup>, Ignacio Mena<sup>6</sup>, Randy A. Albrecht<sup>6</sup>, Indresh Singh<sup>5</sup>, Karen E.  
782 Nelson<sup>5</sup>, Adolfo Garcia-Sastre<sup>6,7</sup>, Chris L. Dupont<sup>1\*</sup>, Rafael A. Medina<sup>2,4,6\*</sup>.

783

784 <sup>1</sup>J. Craig Venter Institute, 4120 Capricorn Lane, La Jolla, CA 92037, USA.

785 <sup>2</sup>Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, Facultad de Medicina,  
786 Pontificia Universidad Católica de Chile, Santiago, Chile.

787 <sup>3</sup> Department of Infectious Diseases, University of California San Diego, La Jolla, CA 92037,  
788 USA

789 <sup>4</sup>Millennium Institute on Immunology and Immunotherapy, Santiago, Chile

790 <sup>5</sup>J. Craig Venter Institute, 9704 Medical Center Drive, Rockville, Maryland 20850, 14 USA.

791 <sup>6</sup>Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of  
792 Medicine at Mount Sinai, New York, NY 10029, USA.

793 <sup>7</sup>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029,  
794 USA.

795 <sup>8</sup>These authors contributed equally to this work


796 <sup>b</sup> Present address: National Center for Immunization and Respiratory Diseases, Centers for  
797 Disease Control and Prevention, Atlanta, GA, USA.



798 <sup>c</sup> Present address: Department of Microbiology and Molecular Medicine, University of Geneva,

799 Switzerland

800 \*Corresponding author: E-mail: [rmedinas@med.puc.cl](mailto:rmedinas@med.puc.cl) , [cdupont@jcvl.org](mailto:cdupont@jcvl.org)



801

802 **Figure S1. Diversity distance analyses of the microbiome of infected and uninfected**


803 **humans.** Box and whisker plots for beta diversity distances within and between influenza types

804 for the human samples (P: Influenza positive, U: Influenza unknown, Flu negative). The boxplots


805 represent the diversity between the different infection types. All the distances were calculated

806 using the Bray-Curtis metric. Red line indicates median in each of the sample groupings and the

807 error bars represent standard deviation.



809 **Figure S2. Relative abundance for the top ten bacterial families in the URT among infected**  
810 **and uninfected human subjects.** The relative abundance values for the most prevalent bacterial  
811 families among the infected (a, b, and c) and uninfected (d) human samples based on the  
812 Bayesian posterior predictive probabilities from the Infinite Dirichlet Multinomial mixture  
813 Models run over 2000 iterations (top to bottom, (a)-(d)).




814

815 **Figure S3. Comprehensive taxonomic breakdown for influenza-infected human subjects.**

816 The plot summarizes an order level breakdown of the Gammaproteobacteria observed in infected


817 patients (top left), and the family level classification (top right) for the same, along with the

818 relative abundances at the **order** level for taxonomic groups that are present in greater than 1%  
819 of the samples (bottom).



821           **Figure S4. Comprehensive temporal taxonomic breakdown for human subjects.** The  
822           plot summarizes the relative taxonomic abundances at the order level across all  
823           timepoints for taxonomic groups that are present in greater than 1% of the four influenza  
824           infected subjects (2 for each virus subtype, A-D clockwise) and 2 healthy subjects (E-F).  
825           Pseudomonadales (pink) is prevalent among the infected individuals (to 4), whereas  
826           inconsistent taxa are seen among the healthy control individuals (bottom 2).  
827





828

829 **Figure S5. Diversity distance analyses of the microbiome of infected and uninfected ferrets.**

830 Box and whisker plots for beta diversity distances within and between influenza types for


831 samples obtained for groups of 7 Infected (I) and 7 Uninfected (U) ferrets. The boxplots

832 represent the diversity between the different infection types. Since there are only two possible

833 infection states for the ferrets, i.e. uninfected and infected, the all-between boxplot is the same as

834 the last boxplot. All the distances were calculated using the Bray-Curtis metric. Red line

835 indicates median in each of the sample groupings and the error bars represent standard deviation.




848 **Figure S6. Relative abundance for the top ten most prevalent bacterial families in the URT**  
849 **among infected and uninfected ferrets.** The relative abundance was determined based on the  
850 Bayesian posterior predictive probabilities from the Infinite Dirichlet multinomial mixture  
851 models run over 1000 iterations. Analysis were performed on pyrosequencing data obtained for  
852 the V1-V3 region of the 16S rRNA of nasal wash samples obtained from 7 ferrets infected (top)  
853 with the A/Netherlands/602/2009 H1N1 virus and from uninfected ferrets (bottom) at the time  
854 points indicated on Fig. 4.



855

856 **Figure S7. Comprehensive taxonomic breakdown for all 14 ferrets.** The plot summarizes the  
857 relative taxonomic abundances at the order level across all timepoints for taxonomic groups that  
858 are present in greater than 5% of the samples (see legend below). *Pseudomonadales* (pink) is  
859 prevalent among the infected ferrets (bottom 7), whereas Clostridiales (dark blue) is the most  
860 abundant among uninfected ferrets (top 7).



861

862 **Figure S8. Temporal diversity distance analyses of the microbiome of infected and**

863 **uninfected ferrets.** Changes in alpha diversity within the uninfected (blue) and infected (red)

864 ferrets during IAV infection. A decrease in alpha diversity was observed among the infected

865 animals during the acute phase of viral infection (3 to 7 dpi), with an eventual recovery. This was

866 in agreement with the *Pseudomonas* bloom observed and the peak IAV titers collected from the

867 same time points. No decreases were observed at any time points for the healthy uninfected

868 group. The boxplots represent the diversity between the different time points. All the distances

869 were calculated using the Kruskal-Wallis method. The line inside the box indicates median in  
870 each of the sample groupings and the error bars represent standard deviation.

871 **Table S1. Clinical-epidemiological characteristics of the hospitalized human patients**  
 872 **diagnosed with Influenza A-like illness, and healthy controls.**

Characteristic	Hospitalized patients			Healthy controls (n=22)
	Total (n=30)	H1N1 positive (n=13)	H3N2 positive (n=15)	
<b>Age</b>				
< 2 years	2	1	1	0
2 - 65 years	17	8	8	22
> 65 years	11	4	6	0
<b>Gender</b>				
Male	15	7	7	10
Female	15	6	8	12
<b>Clinical severity factors</b>				
Hospitalized by Influenza	23	8	13	N/A
CCU by Influenza	11	5	6	N/A
O2 supply	20	8	10	N/A
MV supply	7	5	1	N/A
VAD supply	5	4	1	N/A
<b>Treatments</b>				
Antibiotics	27	12	13	N/A
Antiviral	29	12	15	N/A
<b>Comorbidities</b>				
Asthma	2	0	2	N/A
COPD/Respiratory pediatric disease	3	2	1	N/A
Diabetes	8	3	4	N/A
Obesity	7	3	4	N/A
Cancer	4	3	1	N/A
Cronical cardiovascular disease	12	5	6	N/A
Cronical renal disease	2	2	0	N/A
Neurological disorder	5	2	3	N/A
Severe immunological compromise	9	5	4	N/A
<b>Symptoms</b>				
Fever	24	12	10	N/A
Runny nose	20	9	10	N/A
Throat pain	4	1	3	N/A
Expectoration	22	11	10	N/A
Myalgia	16	8	8	N/A
Conjunctivitis	5	5	0	N/A
<b>Nasopharyngeal samples sequenced</b>				
2 days	3	1	0	0
3 days	4	3	0	0
4 days	6	5	0	1
5 days	12	4	8	1
6 days	5	0	5	20
7 days	3	0	2	0
Day up to 21 dpi.	18	1	15	22

CCU: Clinical Care Unit, MV: Mechanical ventilation, VAD: Vasoactive drugs, COPD: Cronical obstructive pulmonary disease. Dpi: Days post infection. N/A: Not applicable.

873 **Table S2. Two-sided Student's two sample t test results for human samples.** Comparison of  
 874 every pair of boxplots (Fig. S1) to determine if they are significantly different from each other.  
 875 The significance indicates that samples within the same infection state are significantly more  
 876 similar to each other than samples across or between infection states.

Group 1	Group 2	t statistic	Parametric p-value	Parametric p-value (Bonferroni-corrected)
Flu negative vs. Flu negative	All within Infection	-55.0578521	0	0
Flu negative vs. Flu negative	P vs. P	-75.3610857	0	0
Flu negative vs. Flu negative	P vs. U	-138.6375158	0	0
Flu negative vs. Flu negative	U vs. U	-154.3952941	0	0
Flu negative vs. Flu negative	Flu negative vs. P	-221.0081364	0	0
Flu negative vs. Flu negative	All between Infection	-263.0843447	0	0
Flu negative vs. Flu negative	Flu negative vs. U	-291.4056393	0	0
All within Infection	P vs. P	-21.37412196	8.63E-100	2.42E-98
All within Infection	P vs. U	-52.60214147	0	0
All within Infection	U vs. U	-62.86129962	0	0
All within Infection	Flu negative vs. P	-88.60634085	0	0
All within Infection	All between Infection	-150.8209456	0	0
All within Infection	Flu negative vs. U	-140.7417865	0	0
P vs. P	P vs. U	-4.94665465	7.81E-07	2.19E-05
P vs. P	U vs. U	-8.909094618	6.93E-19	1.94E-17
P vs. P	Flu negative vs. P	-24.73696145	9.46E-129	2.65E-127
P vs. P	All between Infection	-24.68676524	9.22E-133	2.58E-131
P vs. P	Flu negative vs. U	-34.22348208	7.20E-246	2.02E-244
P vs. U	U vs. U	-6.730380217	1.80E-11	5.05E-10
P vs. U	Flu negative vs. P	-29.09777915	4.22E-178	1.18E-176
P vs. U	All between Infection	-35.90792139	1.91E-275	5.35E-274
P vs. U	Flu negative vs. U	-48.51917022	0	0
U vs. U	Flu negative vs. P	-21.754135	1.67E-102	4.68E-101
U vs. U	All between Infection	-27.42974294	2.62E-163	7.34E-162
U vs. U	Flu negative vs. U	-40.12946953	0	0
Flu negative vs. P	All between Infection	0.095133236	0.924209718	1
Flu negative vs. P	Flu negative vs. U	-14.55953211	9.70E-48	2.72E-46
All between Infection	Flu negative vs. U	-19.42583244	1.35E-83	3.77E-82



877 **Table S3. Non-parametric multivariate analysis using Anosim and Adonis tests.** Examining  
 878 the effect of clinical parameters (gender, age and antibiotic usage) on the infected human URT  
 879 microbiomes.

<b>Variable</b>	<b>Anosim test</b> (permutations=999)	<b>df</b> (n-1)	<b>Adonis test</b> (permutations=999)	<b>df</b> (n-1)
<b>Gender</b> (n=2; M/F)	R statistic= 0.03124 p-value < 0.023	1	R <sup>2</sup> statistic= 0.0209 p-value < 0.003	1
<b>Antibiotic Usage</b> (n=2; Y/N)	R statistic= -0.046 p-value < 0.732	1	R <sup>2</sup> statistic= 0.01216 p-value < 0.043	1
<b>Age</b> (n=26)	R statistic= 0.4778 p-value < 0.001	25	R <sup>2</sup> statistic= 0.409 p-value < 0.001	25

880

881

882 **Table S4: Random forest analysis results for the human microbiomes.** Ranks range from the  
 883 first few attributes predictive of the infection state, followed by the attributes that are most  
 884 predictive of the data (maximum accuracy).

Rank (1-667)	Ranked attributes (OTUs)	OTU taxonomy	Accuracy (%)
1 <sup>st</sup>	<b>Otu000002</b>	Bacteria;Proteobacteria; Gammaproteobacteria; Pseudomonadales	64.00
2 <sup>nd</sup>	Otu000002; <b>Otu000001</b>	Bacteria;Proteobacteria; Alphaproteobacteria; Rhizobiales; Brucellaceae; Ochrobactrum	64.00
3 <sup>rd</sup>	Otu000002; Otu000001; <b>Otu000003</b>	Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; Pseudomonadaceae; Pseudomonas	62.00
137 <sup>th</sup>	Otu000002; Otu000001; Otu000003; Otu000006; Otu000055; Otu000035; Otu000005, etc (130 other OTUs)		<b>71.00</b>

885

886 **Table S5. Two-sided Student's two sample t test results for ferrets.** Comparison of every pair  
 887 of boxplots (Fig. S4). The significance indicates that samples within the same infection state are  
 888 significantly more similar to each other than samples across or between infection states.

<b>Group 1</b>	<b>Group 2</b>	<b>t statistic</b>	<b>Parametric p-value</b>	<b>Parametric p-value (Bonferroni-corrected)</b>
<b>I vs. I</b>	All within Infection	0.073562	0.941364778	1
<b>I vs. I</b>	U vs. U	0.133209	0.894043353	1
<b>I vs. I</b>	All between Infection	-22.1458	9.17E-100	9.17E-99
<b>I vs. I</b>	I vs. U	-22.1458	9.17E-100	9.17E-99
<b>All within Infection</b>	U vs. U	0.080792	0.935613791	1
<b>All within Infection</b>	All between Infection	-29.1592	1.90E-167	1.90E-166
<b>All within Infection</b>	I vs. U	-29.1592	1.90E-167	1.90E-166
<b>U vs. U</b>	All between Infection	-23.8123	1.24E-113	1.24E-112
<b>U vs. U</b>	I vs. U	-23.8123	1.24E-113	1.24E-112
<b>All between Infection</b>	I vs. U	0	1	1

889

890 **Table S6. Random forest analysis results for the ferret microbiomes.** Ranks range from the  
 891 first few attributes predictive of the infection state, followed by the attributes that are most  
 892 predictive of the data (maximum accuracy).

Rank (1-259)	Ranked attributes (OTUs)	OTU taxonomy	Accuracy (%)
1 <sup>st</sup>	<b>Otu000004</b>	Bacteria;Proteobacteria; Gammaproteobacteria; Pseudomonadales; Moraxellaceae;Acinetobacter	79.79
2 <sup>nd</sup>	Otu000004; <b>Otu000028</b>	Bacteria;Proteobacteria; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae;Enterobacter	91.69
3 <sup>rd</sup>	Otu000004; Otu000028; <b>Otu000017</b>	Bacteria;Firmicutes; Bacilli;Bacillales; Family_XII;Exiguobacterium	89.26
7 <sup>th</sup>	Otu000004; Otu000028; Otu000017; Otu000001; Otu000027; Otu000170; Otu000008		<b>96.47</b>

893